Clinical trials: CIN
Cervical Dysplasia
Digital Imaging Aid for Assessment of Cervical Dysplasia
The overall objective of this study is to evaluate whether polarized or green filtered digital imaging can assist clinicians to screen for premalignant lesions in the cervix.
- Trial name
- NCT00511758
- Testing
- Digital Imaging
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
CIN1, Trichloroacetic Acid
Efficacy of Topical 95% TCA in the Treatment of CIN 1 or Less After Low-grade Abnormality of Screening Test
To evaluate the efficacy of topical 95% TCA in the treatment of CIN 1 or less after low grade abnormality of screening test
- Trial name
- NCT06188104
- Testing
- Trichloroacetic acid
- Where
- Thailand
- Volunteers
- healthy volunteers welcome
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Human Papilloma Virus, Cervical Dysplasia
Educational Video's Impact on Knowledge Regarding Cervical Cancer Screening
The researchers will be conducting a prospective randomized trial where the researchers will be introducing an educational video to see whether there is an increase in knowledge scores surrounding cervical cancer, cervical cancer…
- Trial name
- NCT05756192
- Testing
- Educational video
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- George Washington University
Renal Adverse Events - Contrast Induced Nephropathy (CIN), Non-renal Adverse Events
Adverse Reactions to MR and CT-examinations (Enhanced and Unenhanced)
Rationale: Contrast agents are important tools for MR/CT- examinations, when it comes to diagnosing diseases. But despite their frequent use in Denmark, they are not free of serious and potentially fatal adverse reactions.
- Trial name
- NCT01132339
- Where
- Denmark
- Volunteers
- 1,467 people
- Sponsor
- Copenhagen University Hospital at Herlev
Cervical Intraepithelial Neoplasia Grade 2, DNA Methylation
The Role of FAM19A4 and Hsa-mir-124 Methylation in Predicting Prognosis of Untreated Cervical Intraepithelial Neoplasia 2 (CIN 2)
High-risk precancerous cervical lesions are divided into stage 2 and 3 cervical intraepithelial neoplasia (CIN 2 and 3). CIN 3 represents a direct pre-stage of invasive cancer, has a high rate of progression and a high degree of…
- Trial name
- NCT05624827
- Testing
- Testing DNA methylation test for predicting prognosis of untreated CIN 2
- Where
- Slovenia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Medical Centre Maribor
Cardiovascular Diseases
NITRATE-OCT-CIN (Sub-Study of NITRATE-OCT)
The NITRATE-OCT:- Contrast Nephropathy Sub-study is a proof-of concept single center, randomized, clinical trial designed to ascertain whether a dietary NO3- approach might prove useful adjunctive therapy improving renal function…
- Trial name
- NIT-OCT-CIN (NCT05544981)
- Testing
- Beetroot Juice
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Queen Mary University of London
Cervical Intraepithelial Neoplasia, HPV-Related Cervical Carcinoma
FASTER-Tlalpan Study in Mexico: HPV Vaccination Impact on Cervical Cancer Screening Program
Objective. To evaluate the impact of HPV vaccination as part of a hrHPV-based primary screening program to extend screening intervals. Materials and methods.
- Trial name
- FASTER (NCT03105856)
- Testing
- CERVARIX, GARDASIL
- Where
- Mexico
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Salud Publica, Mexico
Uterine Cervical Neoplasia, Cervix Intraepithelial Neoplasia
Safety and Efficacy Study of Antiviral Local Application to Treat High Grade Cervical Intraepithelial Lesions (CIN2/3)
The purpose of this phase-II study is to evaluate the efficacy and safety of an aqueous gel containing an antiviral, administered directly on cervix exhibiting high grade squamous or glandular intraepithelial lesion (CIN 2 and 3)…
- Trial name
- Colvir-PhaseII (NCT01303328)
- Testing
- C1
- Where
- 9 sites in Belgium
- Volunteers
- 200 people
- Sponsor
- Mithra Pharmaceuticals
Human Papillomavirus
Predictors of CIN Study Series 5.0:Stability Study in Vaginal Self-samples
60 women from the Colposcopy Clinic at the Royal London Hospital will be recruited, having been referred following an abnormal cervical screening result.
- Trial name
- Predictors50 (NCT02622997)
- Testing
- Cervico-vaginal self-sample taken with first flocked swab, Cervico-vaginal self-sample taken with a second flocked swab, Cervico-vaginal self-sample taken with a HerSwab device
- Volunteers
- 60 people
- Sponsor
- Queen Mary University of London
High-risk HPV Infection and Biopsy-proven CIN1
An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101
Phase I, open-label, sequential-cohort, ascending multiple-dose study to evaluate the safety and tolerability of escalating doses of PDS0101 in female subjects with high-risk HPV infection and biopsy-proven CIN1.
- Trial name
- NCT02065973
- Testing
- R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- PDS Biotechnology Corp.
Uterine Cervical Dysplasia
LLETZ Under Direct Colposcopic Vision
To assess the benefits of large Loop excision of the transformation Zone (LLETZ) under direct colposcopic Vision.
- Trial name
- NCT02910388
- Testing
- LLETZ with colposcopy, LLETZ without colposcopy
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Zydolab - Institute of Cytology and Immune Cytochemistry
Cervical Cancer, Genital Wart
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
This study will evaluate the immunogenicity and safety of Zerun 9-valent HPV recombinant vaccine in healthy female 16-26 years of age by comparing with GARDASIL®9.
- Conditions
- Cervical Cancer, Genital Wart, CIN, VIN
- Trial name
- NCT05580341
- Testing
- Zerun HPV-9, GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Endometrial Cancer, Cervical Cancer
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human…
- Conditions
- Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia
- Trial name
- ECHO (NCT05051722)
- Testing
- Vaginal Fluid Collection, Blood Collection
- Where
- 25 sites in United States
- Volunteers
- 3,110 people
- Sponsor
- Mayo Clinic
HPV Disease, Cervical Intraepithelial Neoplasia Grade I
HIFU vs Observation for LSIL of Cervix: A Randomized Controlled Trial
The majority of low-grade pre-invasive lesions of cervix (low-grade squamous intraepithelial lesions, LSIL).will regress spontaneously over 2 years and immediate treatment may not be necessary.
- Trial name
- HIFU Colpo (NCT07461064)
- Testing
- HIFU treatment
- Volunteers
- 180 people
- Sponsor
- Queen Mary Hospital, Hong Kong
Cervical Cancer, Cervical Cancer Screening
Human Papillomavirus Self-sampling for Enhancing Cervical Screening During the War in Ukraine
In 2020, a cervical screening center was established in Zaporizhzhia (Ukraine), initiating a pilot project to evaluate the prevalence of HPV among women in Eastern Ukraine.
- Conditions
- Cervical Cancer, Cervical Cancer Screening, Human Papillomavirus (HPV) Infection, Cervical Intraepithelial Neoplasia
- Trial name
- NCT07275333
- Testing
- HPV Self-Sampling Kit
- Where
- Ukraine
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Cervical Intraepithelial Neoplasia 3
Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.
This is a study to investigate the safety and efficacy of GX-188E administered IM plus local administration of GX-I7 or Imiquimod at cervix in subjects with cervical intraepithelial neoplasia (CIN) 3.
- Trial name
- NCT03206138
- Testing
- GX-188E, GX-I7, GX-188E, Imiquimod
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Seoul St. Mary's Hospital
Cervical Intraepithelial Neoplasia Grade 1, Cervical Intraepithelial Neoplasia Grade 2
TRICIN: Prospective Study on the Efficacy of Single Topical Trichloroacetic Acid (TCA) 85% in the Treatment of Cervical Intraepithelial Neoplasia (CIN 1/2)
Trichloroacetic acid 85% =TCA is an investigational device intended to achieve a complete histologic remission in individuals with cervical intraepithelial neoplasia (CIN) grade 1/2.
- Trial name
- TRICIN (NCT04400578)
- Testing
- Trichloroacetic acid 85% (TCA)
- Where
- Austria
- Volunteers
- 102 people
- Sponsor
- Krankenhaus Barmherzige Schwestern Linz
Cervix Carcinoma
Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix
The goal of this clinical research study is to learn if it is possible to get high-resolution microendoscopy (HRME) images of AIS tissue and/or tissue from microinvasive carcinoma right before a biopsy of the cervix.
- Trial name
- NCT02206048
- Testing
- Proflavine, High-Resolution Microendoscopy (HRME) Imaging
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Intraepithelial Neoplasia
Testing Use of Condoms on Regression of Cervical Intraepithelial Neoplasia
Women who are diagnosed with CIN2 and who have a pregnancy wish are followed up 6 months after the diagnosis with new examinations. The regression rate is based solely on the woman's own ability to clear the cervical lesions.
- Trial name
- NCT02907333
- Testing
- Advice to use condoms
- Where
- Denmark
- Volunteers
- 285 people
- Sponsor
- University of Copenhagen
Human Papilloma Virus Infection
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
This trail is to evaluate the safety profile of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli) in healthy Chinese women ages 20-45 and determine the optimal ratio of…
- Trial name
- NCT05694728
- Testing
- Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli), Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)
- Where
- China
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc